Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IACH 2021 | Advances in chronic GvHD management

Zinaida Perić • 28 Sep 2021
IACH 2021
Anti-thymocyte globulin Cyclophosphamide Cyclosporine Mycophenolate mofetil

Zinaida Perić, MD, PhD, University Hospital Centre Zagreb, Zagreb, Croatia, gives an overview of her talk on advances in the management of chronic graft-versus-host disease (GvHD). Recent improvements in the treatment of chronic GvHD include antithymocyte globulin (ATG) and post-transplant cyclophosphamide. Clinical trials are currently evaluating the use of post-transplant cyclophosphamide in combination with cyclosporine compared to standard immunosuppression with cyclosporine and mycophenolate mofetil (MMF) and have shown that adding post-transplant cyclophosphamide significantly reduces chronic GvHD and leads to improvements in GvHD-free relapse-free survival. This interview took place at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), which took place virtually in 2021.

More from Zinaida Perić

2:56
Ibrutinib, ruxolitinib & belumosudil for SR-cGvHD
Zinaida Perić • 28 Sep 2021
2:13
Next steps in chronic GvHD
Zinaida Perić • 28 Sep 2021
9:45
Management of chronic GvHD
Zinaida Perić • 25 Jun 2020
6:02
Amniotic membrane transplantation in ocular GvHD
Zinaida Perić • 25 Jun 2020
The content of VJHemOnc is intended for healthcare professionals